Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

281. Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus Full Text available with Trip Pro

Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus Overwhelming evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have anti-tumour activity and the potential to prevent cancer, particularly colorectal cancer. However, the mechanisms underlying this effect remain hypothetical. Dysregulation of the nuclear factor-kappaB (NF-κB) transcription factor is a common event in many cancer types which contributes to tumour (...) initiation and progression by driving expression of pro-proliferative/anti-apoptotic genes. In this review, we will focus on the current knowledge regarding NSAID effects on the NF-κB signalling pathway in pre-cancerous and cancerous lesions, and the evidence that these effects contribute to the anti-tumour activity of the agents. The nuclear organelle, the nucleolus, is emerging as a central regulator of transcription factor activity and cell growth and death. Nucleolar function is dysregulated

2017 Biomedicines

282. Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation Full Text available with Trip Pro

Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation The development of cancer involves uncontrolled cell proliferation, and multiple signaling pathways that regulate cell proliferation have been found to be dysregulated in cancers. Extracellular signal-regulated protein kinase (ERK) is one of three major subtypes in the mitogen-activated protein kinase (MAPK) families. The MAPK/ERK pathway (RAS/RAF1/MEK/ERK) plays an important part in promoting cell (...) proliferation in response to growth factors, thereby serving as a driving signal in gastrointestinal (GI) tumors. In contrast, the p53 tumor suppressor functions as a "guardian of the genome" and stops cell proliferation when oncogenic signaling is activated.Both pathways constrain each other in healthy GI epithelium, facilitating controlled proliferation that is essential for tissue repair and regeneration. However, in GI tumors, the MAPK/ERK and p53 pathways are commonly dysregulated, in part due

2017 Gastrointestinal tumors

283. The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma Full Text available with Trip Pro

The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma Colorectal cancer is the most common malignancy of the gastrointestinal tract with very high mortality. One of the most distinguishing features for the establishment of an epithelial-mesenchymal transition phenotype is the alteration of mesenchymal markers expression and structural adhesion proteins. We evaluated the significance of vimentin (...) and fibronectin gene expression in relation to invasion and metastasis in CRC patients. Tissue specimens were collected consecutively from forty-five colorectal carcinoma patients during surgeries. Tissues were divided into two separate parts for pathological and molecular assays. In order to histological staging, tissue sections were prepared from formalin-fixed paraffin-embedded blocks and stained with Hematoxylin and Eosin. To quantify gene expression, specimens were dissected and homogenized. Moreover

2017 EXCLI journal

284. ASCO: practice changing studies in gastrointestinal cancer Full Text available with Trip Pro

ASCO: practice changing studies in gastrointestinal cancer 28761760 2017 08 01 2059-7029 2 3 2017 ESMO open ESMO Open ASCO: practice changing studies in gastrointestinal cancer. e000228 10.1136/esmoopen-2017-000228 Prager Gerald G Department of Medicine, Comprehensive Cancer Center, Medical University Vienna, Austria, Vienna, Austria. eng Journal Article 2017 07 05 England ESMO Open 101690685 2059-7029 gastrointestinal cancer Competing interests: None declared. 2017 06 01 2017 8 2 6 0 2017 8 2

2017 ESMO open

285. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial (Abstract)

Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate (...) , or colorectal cancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT

2017 EvidenceUpdates

286. The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations The clinical effectiveness of different (...) surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A & Duffy S W Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2017 Health Technology Assessment (HTA) Database.

287. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database Full Text available with Trip Pro

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled (...) in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.

2017 EvidenceUpdates

288. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry (Abstract)

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry The objective of this study was (a) To know the prevalence and distribution of extracolonic cancer (EC) in patients with inflammatory bowel disease (IBD); (b) To estimate the incidence rate of EC; (c) To evaluate the association between EC and treatment with immunosuppressants and anti-tumor necrosis factor (TNF) agents.This was an observational cohort study.IBD and inclusion in the ENEIDA Project

2017 EvidenceUpdates

289. Effect of Intrathecally Administered Ketamine, Morphine, and Their Combination Added to Bupivacaine in Patients Undergoing Major Abdominal Cancer Surgery a Randomized, Double-Blind Study Full Text available with Trip Pro

Effect of Intrathecally Administered Ketamine, Morphine, and Their Combination Added to Bupivacaine in Patients Undergoing Major Abdominal Cancer Surgery a Randomized, Double-Blind Study Effective postoperative pain control reduces postoperative morbidity. In this study, we investigated the effects of intrathecal morphine, ketamine, and their combination with bupivacaine for postoperative analgesia in major abdominal cancer surgery.Prospective, randomized, double-blind.Academic medical (...) with group M until six hours postoperation. No other side effects were observed.Adding intrathecal ketamine 0.1 mg/kg to morphine 0.3 mg in patients who underwent major abdominal cancer surgery reduced the total postoperative morphine consumption in comparison with either drug alone, with an overall good postoperative analgesia in all groups, with no side effects apart from sedation.

2017 EvidenceUpdates

290. Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy Full Text available with Trip Pro

Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy 28713863 2018 11 13 2415-1289 2 2017 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Another brick in the large wall against colorectal cancer: a commentary on effectiveness of screening colonoscopy. 59 10.21037/tgh.2017.06.02 Glazer Yair Y Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Perry Zvi H ZH Department of Surgery (...) A, Soroka University Medical Center, Beer Sheva, Israel. Department of Epidemiology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Avital Itzhak I Department of Surgery A, Soroka University Medical Center, Beer Sheva, Israel. Soroka University Comprehensive Cancer Center, Beer-Sheva, Israel. Department of Healthcare Sciences, Ben-Gurion University, Beer-Sheva, Israel. eng Editorial Comment 2017 06 30 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gut. 2016 Oct 12;: 27733426 Conflicts

2017 Translational gastroenterology and hepatology

291. Mortality and Survival after Surgical Treatment of Colorectal Cancer in Patients Aged over 80 Years Full Text available with Trip Pro

Mortality and Survival after Surgical Treatment of Colorectal Cancer in Patients Aged over 80 Years The purpose of this study was to identify the clinical factors and tumor characteristics that predict the outcome of colorectal cancer patients aged >80 years.The data of 186 patients aged >80 years with colorectal cancer were collected from a computer database, and the variables were analyzed by both uni- and multivariate analyses.The 30-day mortality was 4% and the 90-day mortality 10%. The 1 (...) -year survival was 76%, and 27 (61%) of the 44 deaths were unrelated to cancer. The overall 5-year survival was 36%, the median survival 38 months, and the cancer-specific survival 40%. The recurrence rate after radical surgery was 22% and it was not affected by age. Kaplan-Meier estimates indicated that age, number of underlying diseases, radical operation, Union for International Cancer Control stage of the tumor, tumor size, number of lymph nodes involved, venous invasion, and recurrent disease

2017 Gastrointestinal tumors

292. Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line

Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer - third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search (...) will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line Atezolizumab (Tecentriq) and Cobimetinib (Cotellic) for advanced/metastatic colorectal cancer – third line June 2017 The combination of atezolizumab (Tecentriq), given by injection, and cobimetinib (Cotellic), given orally, is being developed to increase the options available

2017 NIHR Innovation Observatory

293. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Full Text available with Trip Pro

colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015.Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient.The primary end point was overall survival. Secondary objectives included progression-free survival and overall (...) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown.To determine if the addition

2017 JAMA Controlled trial quality: predicted high

294. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. (Abstract)

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years

2017 BMJ

295. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. Full Text available with Trip Pro

were determined in both validation cohorts at 1, 5, and 10 years.Results The final models included the following variables in men and women: age, deprivation score, cancer stage, cancer grade, smoking status, colorectal surgery, chemotherapy, family history of bowel cancer, raised platelet count, abnormal liver function, cardiovascular disease, diabetes, chronic renal disease, chronic obstructive pulmonary disease, prescribed aspirin at diagnosis, and prescribed statins at diagnosis. Improved (...) survival in women was associated with younger age, earlier stage of cancer, well or moderately differentiated cancer grade, colorectal cancer surgery (adjusted hazard ratio 0.50), family history of bowel cancer (0.62), and prescriptions for statins (0.77) and aspirin (0.83) at diagnosis, with comparable results for men. The risk equations were well calibrated, with predicted risks closely matching observed risks. Discrimination was good in men and women in both validation cohorts. For example, the five

2017 BMJ

296. Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Full Text available with Trip Pro

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports 29114600 2018 11 13 2452-1094 2 3 2017 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports. 333-338 10.1016/j.adro.2017.06.001 Ebner Daniel K DK Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology, Chiba (...) 05 31 2017 06 01 2017 11 9 6 0 2017 11 9 6 0 2017 11 9 6 1 epublish 29114600 10.1016/j.adro.2017.06.001 S2452-1094(17)30101-X PMC5605310 J Immunother Cancer. 2016 Sep 20;4:51 27660705 Anticancer Res. 2007 Jan-Feb;27(1B):499-503 17348433 Nat Rev Clin Oncol. 2016 Aug;13(8):516-24 26951040 Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):293-5 22560555 Oncoimmunology. 2014 May 14;3:e28780 25083318 Cancer Lett. 2015 Jan 1;356(1):82-90 24125863 Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70

2017 Advances in radiation oncology

297. Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers Full Text available with Trip Pro

Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers Gastrointestinal stromal tumors (GIST) comprise about 80% of gastrointestinal sarcomas. In patients with localized disease, surgery is considered as "Gold Standard" treatment. Organ-sparing radical en-block resection is widely accepted practice. Since lymph node dissection is not routinely indicated, minimally invasive approach is of particular interest. The aim (...) of this study is to investigate the short-term outcomes of different surgical treatment of GISTs.We analyzed data of 116 patients who received surgical treatment for localized forms of GIST. Tumors were located in the stomach in 87 (75%) cases, in the small intestine in 26 (22.4%) cases, and extragastrointestinal GISTs were found in 3 (2.6%) patients. Four different approaches were used-open surgery (OpS, n=48), laparoscopic surgery (LS, n=40), endoscopic procedures (EP, n=22) and hybrid rendezvous (HR, n=6

2017 Translational gastroenterology and hepatology

298. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model Full Text available with Trip Pro

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model Approximately 10% of colorectal cancers harbor BRAFV600E mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF (...) ), cobimetinib (MEK), and GDC-0994 (ERK) combinations. Preclinical data was used to develop a mechanism-based computational model linking cell surface receptor (EGFR) activation, the MAPK signaling pathway, and tumor growth. Clinical predictions of anti-tumor activity were enabled by the use of tumor response data from three Phase 1 clinical trials testing combinations of EGFR, BRAF, and MEK inhibitors. Simulated responses to GDC-0994 monotherapy (overall response rate = 17%) accurately predicted results

2017 NPJ systems biology and applications

299. Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown.To determine the combined effect of a CRC screening decision

2017 EvidenceUpdates

300. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr Full Text available with Trip Pro

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods (...) for the probability of surviving beyond 10 years. Conclusion This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic

2017 EvidenceUpdates